3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neuroendocrine Tumors
1
Multiple Myeloma
1
Advanced Solid Tumors
1
Interventions
Injections
7
pembrolizumab
5
Paclitaxel
5
Bevacizumab
5
Leucovorin
4
Fluorouracil
4
Carboplatin
4
trifluridine tipiracil drug combination
3
Pemetrexed
3
Oxaliplatin
3
Irinotecan
3
Docetaxel
3
Capecitabine
3
toripalimab
2
tislelizumab
2
fludarabine
2
Nivolumab
2
Gemcitabine
2
Fulvestrant
2
Cisplatin
2
BMS-753493
2
130-nm albumin-bound paclitaxel
2
urelumab
1
ulixertinib
1
palbociclib
1
mogamulizumab
1
lenvatinib
1
fluzoparib
1
duvelisib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Advanced Solid Tumors
×
Antiemetics
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts